Error-corrected next-generation sequencing to advance nonclinical genotoxicity and carcinogenicity testing
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 per month
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Rent or buy this article
Get just this article for as long as you need it
Prices may be subject to local taxes which are calculated during checkout
Nature Reviews Drug Discovery 22, 165-166 (2023)
We thank the Health and Environmental Sciences Institute (HESI) of the Genetic Toxicology Technical Committee (GTTC) members for their scientific input. All authors are members of the HESI GTTC. This article reflects the views of the authors and does not necessarily reflect the official views or policy of the US Food and Drug Administration, the National Institutes of Health, or the US government.
Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646–674 (2011).
Salk, J. J., Schmitt, M. W. & Loeb, L. A. Enhancing the accuracy of next-generation sequencing for detecting rare and subclonal mutations. Nat. Rev. Genet. 19, 269–285, (2018).
Wang, Y. et al. Genetic toxicity testing using human in vitro organotypic airway cultures: assessing DNA damage with the CometChip and mutagenesis by Duplex Sequencing. Environ. Mol. Mutagen. 62, 306–318 (2021).
Valentine, C. C. III et al. Direct quantification of in vivo mutagenesis and carcinogenesis using duplex sequencing. Proc. Natl Acad. Sci. USA 117, 33414–33425 (2020).
Fielden, M. R. et al. Modernizing human cancer risk assessment of therapeutics. Trends Pharmacol. Sci. 39, 232–247 (2018).
J.J.S. is an employee and equity holder at TwinStrand Biosciences Inc., and is an author on one or more duplex sequencing-related patents. R.C., J.E., P.A.E., T.H. Jr, D.K., A.M.L., J.J.S., S.Z. and S.M. are employed by companies that may be engaged in using error-corrected sequencing.